{"product_id":"epas1-antibody-sc-f1087","title":"HIF-2α Antibody","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003eEPAS1 is a target of interest in many antibody-based workflows. Cells, tissues, and organisms experience reduced oxygen levels, or \"hypoxia,\" under both physiological and pathological conditions. During early embryonic development, the rapid proliferation of cells creates a state of physiological hypoxia, which drives the formation of the hematopoietic and circulatory systems. The hypoxia-inducible factors (HIFs) are critical mediators of the cellular and systemic adaptive response to low oxygen availability. Depending on the literature source, EPAS1 may also be discussed as HIF-2alpha and HIF-2 alpha.\u003c\/p\u003e\u003cp\u003eReported cellular context includes nucleus, which can matter when signal is compared across treatments or changing cell states. Following EPAS1 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eEPAS1 is commonly interpreted in the context of cancer and developmental biology research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans nucleus, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.\u003c\/p\u003e\u003cp\u003eConsider these angles when interpreting target-level changes:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003esignal enrichment within nucleus relative to the broader cellular background\u003c\/li\u003e\n\u003cli\u003echanges associated with proliferative state, oncogenic signaling, or treatment response\u003c\/li\u003e\n\u003cli\u003estage-dependent patterns during differentiation, morphogenesis, or lineage commitment\u003c\/li\u003e\n\u003cli\u003eco-patterning with orthogonal markers and control conditions that clarify pathway state\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eVariant Considerations\u003c\/h2\u003e\u003cp\u003eIf your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for EPAS1. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.\u003c\/p\u003e\u003cp\u003eStandardize sampling time, control choice, and downstream analysis thresholds so apparent differences in EPAS1 reflect biology rather than handling. When interpreting EPAS1, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.\u003c\/p\u003e\u003cp\u003eFor multi-run studies, a shared reference condition can keep EPAS1 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"20 µl","offer_id":57577608446297,"sku":"F1087-20UL","price":149.0,"currency_code":"EUR","in_stock":true},{"title":"100 µl","offer_id":57577608479065,"sku":"F1087-100UL","price":329.0,"currency_code":"EUR","in_stock":true},{"title":"2 × 100 µl","offer_id":57577608511833,"sku":"F1087-2X100UL","price":489.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/F1087-wb.gif?v=1773599274","url":"https:\/\/absource-diagnostics.myshopify.com\/products\/epas1-antibody-sc-f1087","provider":"Absource Diagnostics","version":"1.0","type":"link"}